Compare KSCP & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | JSPR |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7M | 68.4M |
| IPO Year | 2022 | N/A |
| Metric | KSCP | JSPR |
|---|---|---|
| Price | $4.76 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $16.67 | ★ $25.60 |
| AVG Volume (30 Days) | 365.4K | ★ 3.8M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,610,000.00 | N/A |
| Revenue This Year | $8.68 | N/A |
| Revenue Next Year | $32.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.50 | N/A |
| 52 Week Low | $2.45 | $1.39 |
| 52 Week High | $17.79 | $23.11 |
| Indicator | KSCP | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 46.29 |
| Support Level | $4.35 | $1.60 |
| Resistance Level | $5.06 | $1.93 |
| Average True Range (ATR) | 0.33 | 0.20 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 43.16 | 36.90 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.